TFPI ALPHA AND TFPI BETA
TFPI 阿尔法和 TFPI 贝塔
基本信息
- 批准号:8497704
- 负责人:
- 金额:$ 35.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-07-15 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AnticoagulantsAtherosclerosisBindingBiological AssayBloodBlood CirculationBlood Coagulation DisordersBlood PlateletsBone Marrow TransplantationCell surfaceCoagulation ProcessComplexEndothelial CellsEndotoxemiaFactor VFactor VIIaFactor XaFeedbackGPI Membrane AnchorsGenesGenomeGoalsHuman ActivitiesInflammationInjuryIntronsInvestigationLipoprotein BindingLipoproteinsMessenger RNAMethodsModelingMononuclearMouse StrainsMusPlasmaPlasma CellsPlayProtease InhibitorProtein IsoformsProtein SProteinsRelative (related person)RoleSiteStagingStructureStructure of thyroid parafollicular cellTFPITestingThromboplastinThrombosisTransgenesTransgenic MiceWalkingfetalhuman tissuein vivointerestmouse modelpublic health relevancetissue-factor-pathway inhibitor 2transgene expression
项目摘要
DESCRIPTION (provided by applicant): Tissue factor pathway inhibitor (TFPI) produces factor Xa (FXa)-dependent feedback inhibition of factor VIIa/tissue factor (FVIIa/TF)-induced coagulation. In humans, TFPI is expressed as two isoforms. TFPI1 contains three tandem Kunitz-type protease inhibitor domains, Kunitz-1 binds FVIIa in the FVIIa/TF complex and the second binds FXa. Kunitz-3 does not possess protease inhibitor activity. TFPI2 lacks the Kunitz-3 and the C-terminus of TFPI1. The latter is required for TFPI1's optimal inhibition of FXa and its anticoagulant activity in one-stage coagulation assays. TFPI1 interacts with protein S (PS), which enhances its anti-FXa activity, and with factor V (FV), which may prolong its clearance from plasma. Both forms of TFPI associate with the surface of cells in a glycosylphosphatidylinositol (GPI)-anchor dependent fashion, but through different mechanisms. TFPI1, present in plasma and secreted by activated platelets, appears to bind to another GPI-anchored protein(s), whereas TFPI2 contains an intrinsic GPI-anchor. We plan to determine the structures within TFPI1 responsible for its binding to PS and FV and further explore its interactions with cell surfaces. The form(s) of TFPI, which circulate bound to lipoproteins, will be identified and the relevance of a potential additional isoform of TFPI, TFPI4, will be investigated. TFPI gene-disrupted mice (TFPI KO) die intrautero of widespread thrombosis and a consumptive coagulopathy, but are rescued by a low level of either of two transgenes with FVIIa/TF inhibitory activity. One, Tie2-hTFPI1, directs expression in endothelial cells, the other, Tf-mXK1-hAlb directs expression into plasma. Transgene-rescued TFPI KO mice and appropriate bone marrow transplantation studies will be used to assess the role of platelet- associated TFPI1 and to determine the effect of low levels of endogenous TFPI on thrombosis, inflammation, and atherosclerosis using mouse models.
描述(由申请方提供):组织因子途径抑制剂(TFPI)对因子VIIa/组织因子(FVIIa/TF)诱导的凝血产生因子Xa(FXa)依赖性反馈抑制。在人类中,TFPI表达为两种同种型。TFPI 1含有三个串联的Kunitz型蛋白酶抑制剂结构域,Kunitz-1结合FVIIa/TF复合物中的FVIIa,第二个结合FXa。Kunitz-3不具有蛋白酶抑制剂活性。TFPI 2缺少Kunitz-3和TFPI 1的C-末端。后者是TFPI 1对FXa的最佳抑制及其在一期凝血试验中的抗凝活性所需的。TFPI 1与蛋白S(PS)相互作用,增强其抗FXa活性,并与因子V(FV)相互作用,可延长其从血浆中的清除。两种形式的TFPI以糖基磷脂酰肌醇(GPI)-锚依赖性方式与细胞表面缔合,但通过不同的机制。存在于血浆中并由活化的血小板分泌的TFPI 1似乎与另一种GPI锚定蛋白结合,而TFPI 2含有内在的GPI锚。我们计划确定TFPI 1内负责其与PS和FV结合的结构,并进一步探索其与细胞表面的相互作用。将鉴定与脂蛋白结合的TFPI循环形式,并研究TFPI潜在的其他亚型TFPI 4的相关性。TFPI基因破坏的小鼠(TFPI KO)死于子宫内广泛的血栓形成和消耗性凝血病,但被低水平的两种具有FVIIa/TF抑制活性的转基因中的任一种所拯救。一种是Tie 2-hTFPI 1,其在内皮细胞中指导表达,另一种是Tf-mXK 1-hAlb,其在血浆中指导表达。转基因挽救的TFPI KO小鼠和适当的骨髓移植研究将用于评估血小板相关TFPI 1的作用,并使用小鼠模型确定低水平内源性TFPI对血栓形成、炎症和动脉粥样硬化的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEORGE J BROZE其他文献
GEORGE J BROZE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEORGE J BROZE', 18)}}的其他基金
相似海外基金
A lipid-induced RNA-binding protein in atherosclerosis
动脉粥样硬化中脂质诱导的 RNA 结合蛋白
- 批准号:
10363664 - 财政年份:2020
- 资助金额:
$ 35.81万 - 项目类别:
A lipid-induced RNA-binding protein in atherosclerosis
动脉粥样硬化中脂质诱导的 RNA 结合蛋白
- 批准号:
10586123 - 财政年份:2020
- 资助金额:
$ 35.81万 - 项目类别:
Functional analysis of ApoA-I/HDL binding protein for the treatment of atherosclerosis(Fostering Joint International Research)
ApoA-I/HDL结合蛋白治疗动脉粥样硬化的功能分析(促进国际联合研究)
- 批准号:
16KK0203 - 财政年份:2017
- 资助金额:
$ 35.81万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research)
Development of diagnostic method for atherosclerosis targeting adipokine binding proteins
开发针对脂肪因子结合蛋白的动脉粥样硬化诊断方法
- 批准号:
15H04762 - 财政年份:2015
- 资助金额:
$ 35.81万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Role of a novel IL18 binding protein in atherosclerosis
新型 IL18 结合蛋白在动脉粥样硬化中的作用
- 批准号:
8882740 - 财政年份:2015
- 资助金额:
$ 35.81万 - 项目类别:
Role of a novel IL18 binding protein in atherosclerosis
新型 IL18 结合蛋白在动脉粥样硬化中的作用
- 批准号:
9130248 - 财政年份:2015
- 资助金额:
$ 35.81万 - 项目类别:
Progranulin, a Novel HDL-Binding Protein, Suppresses Systemic Inflammation, Glucose Abnormality and Atherosclerosis
颗粒体蛋白前体是一种新型 HDL 结合蛋白,可抑制全身炎症、血糖异常和动脉粥样硬化
- 批准号:
24390233 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
S100A8/9 calcium binding proteins enhances myeloid cell proliferation and impairs atherosclerosis regression in diabetes
S100A8/9 钙结合蛋白增强骨髓细胞增殖并损害糖尿病患者的动脉粥样硬化消退
- 批准号:
252764 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别: